Listed

Prelude Therapeutics Inc: Form 10-Q for the period ended Sep 30, 2021

Filed with the SEC on Nov 12, 2021 and accepted by EDGAR at Nov 12, 2021, 08:28 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2021-07-01 to 2021-09-30$22.7mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2021-01-01 to 2021-09-30$61.6mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2021-07-01 to 2021-09-30−$30.8mus-gaap:OperatingIncomeLoss
Operating income9 months2021-01-01 to 2021-09-30−$80.7mus-gaap:OperatingIncomeLoss
Net income3 months2021-07-01 to 2021-09-30−$30.7mus-gaap:NetIncomeLoss
Net income9 months2021-01-01 to 2021-09-30−$78.9mus-gaap:NetIncomeLoss
Operating cash flow9 months2021-01-01 to 2021-09-30−$57.8mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2021-01-01 to 2021-09-30$2.0mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2021-09-30$61.4mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-09-30$325.9mus-gaap:AssetsCurrent
Total assetsAt period end2021-09-30$331.2mus-gaap:Assets
Current liabilitiesAt period end2021-09-30$19.7mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-09-30$20.0mus-gaap:Liabilities
Shareholders' equityAt period end2021-09-30$311.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001564590-21-056509. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.